Page 157 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes

galantamine 24 mg/d placebo galantamine 32 mg/d 75.3 75.0 75.9 61.5 58.8 65.6 92 90 92 95.3% 91.9% 94.3% 19.2 19.1 19.5 Primary Outcome Measures: ADAS-Cog 11; CIBIC-plus Secondary Outcome Measures: ADAS-Cog 13; ADAS-Cog 11 responders (≥ 4 point improvement); Timing of assessments: Baseline and 3 weeks, 3 months, 6 months Health Outcome Measures: No significant differences between treatment groups in the mean change in total DAD score from baseline Intermediate Outcome Measures: ADAS-Cog 13: NR GAL-treated patients showed significan

DAD • • • • •

Final Report Update 1 Authors: Raskind et al. Year: 2000 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% white): Other germane population qualities: Other medical conditions • MMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs